A Phase 1 Study of Two PRN1008 Tablet Formulations and the impact of Midazolam and Famotidine on PRN1008 in Healthy Subjects
Phase 1
Completed
- Conditions
- Immune-related disorders,
- Registration Number
- ACTRN12618000249257
- Lead Sponsor
- Principia Biopharma Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method